Q-Line Biotech Ltd (QLINE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Q-Line Biotech Ltd on NSE and BSE, with an AI summary of each filing.
Q-Line Biotech Limited has informed the Exchange regarding voting results of Annual General Meeting held on September 30, 2026 and Scrutinizer Report
Annual General Meeting · 02 Oct 2026, 12:06 am
Q-Line Biotech Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026
Annual General Meeting · 01 Oct 2026, 11:33 pm
Q-Line Biotech Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
Annual General Meeting · 01 Oct 2026, 1:02 am
Q-Line Biotech Limited has informed the Exchange regarding 'The dispatch of the Notice of the Annual General Meeting scheduled to be held on September 30, 2026, to the shareholders whose registered email addresses could not be delivered due to email bounce-back, in accordance with Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.'.
Annual General Meeting · 12 Sept 2026, 12:51 am
Q-Line Biotech Limited has informed the Exchange regarding 'Corrigendum to the Intimations dated 07.09.2026 Correction in the Number of the Annual General Meeting and Notice of Annual General Meeting as mentioned in the subject of the intimations'.
Annual General Meeting · 08 Sept 2026, 10:58 pm
Q-Line Biotech Limited has informed the Exchange regarding 'Q-Line Biotech Limited has informed the Exchange about the Annual Report_2025-26 along with Notice of 37th Annual General Meeting along with and other information/communication to Shareholders, pursuant to Regulation 30, 34 and 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.'.
Annual General Meeting · 07 Sept 2026, 11:44 pm
Q-Line Biotech Limited has informed the Exchange about the Annual Report_2025-26 along with Notice of 37th Annual General Meeting along with and other information/communication to Shareholders, pursuant to Regulation 30, 34 and 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Annual General Meeting · 07 Sept 2026, 11:42 pm
Q-Line Biotech Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
Annual General Meeting · 07 Sept 2026, 11:08 pm
Q-Line Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026.
Outcome · 05 Sept 2026, 11:45 pm
Q-Line Biotech Board Approves 16th AGM, Director Reappointments, and Cost Auditor Q-Line Biotech Limited’s Board approved the FY26 Board’s Report and convened its 16th AGM physically for 30th Sep'26 in Lucknow. The cut-off date for e-voting is 23rd Sep'26, with the remote e-voting window active from 27th Sep'26 to 29th Sep'26 via CDSL, scrutinized by M/s. MMA & Partners. Additionally, the Board recommended the re-appointment of Whole Time Directors Ajay Kumar Mahanty and Kuldeep Chowdhry (liable to retire by rotation) and approved M/s P S P & Associates as Cost Auditor for FY27.
To consider other business matters
Others (Uncategorized) · 05 Sept 2026, 12:39 am
Q-Line Biotech Schedules Board Meeting for 16th AGM Approvals and Cost Auditor Appointment Q-Line Biotech Limited has scheduled a Board of Directors meeting on 5th Sep'26 to consider and approve key corporate actions. The agenda includes approving the Directors' Report for the financial year ended 31st Mar'26, finalising the notice and schedule for the 16th Annual General Meeting, fixing the cut-off date for e-voting, and recommending director appointments. Additionally, the board will evaluate the appointment and remuneration of M/s P S P & Associates as Cost Auditor for FY 2026-27, subject to shareholder ratification.
Q-LINE BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 05-Sep-2026 to consider Other business.
Intimation · 05 Sept 2026, 12:14 am
Q-Line Biotech Schedules Board Meeting on 5th Sep'26 for General Business Q-Line Biotech Limited has notified the exchange that a meeting of its Board of Directors is scheduled to be held on 5th Sep'26 to discuss and consider other general business matters.
Q-Line Biotech Limited has informed the Exchange regarding a press release dated September 02, 2026, titled "Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Amended and Restated License Agreement with Boule Medical AB, Sweden".
Press Release · 02 Sept 2026, 11:24 pm
Q-Line Biotech Secures 25% Royalty Reduction in Amended Agreement with Boule Medical Q-Line Biotech entered an amended license agreement with Sweden's Boule Medical AB for diagnostic reagents and haematology analyzers. A key commercial benefit is a 25% reduction in license and royalty costs payable to Boule, effective 1st Jul'26. The revised framework includes rationalized minimum purchase commitments, extended payment terms, and volume-linked benefits, enhancing Q-Line's cost efficiency in price-sensitive institutional markets. The agreement has an initial 5-year term, extendable by another 5 years, positioning the company for deeper market penetration, higher instrument placements, and increased recurring reagent volumes.
Q-Line Biotech Limited has informed the Exchange about Credit Rating- New
Others (Uncategorized) · 22 Aug 2026, 10:42 pm
Q-Line Biotech Receives Initial Credit Ratings from CARE CARE Ratings has assigned initial credit ratings to Q-Line Biotech's bank facilities totaling ₹221.30 crore as of 21 Aug'26. The company received a 'CARE A-; Stable' rating for its ₹20.00 crore long-term facilities and 'CARE A-; Stable / CARE A2+' for its ₹185.30 crore long-term/short-term facilities. Additionally, its ₹16.00 crore short-term facilities were assigned a 'CARE A2+' rating. These ratings are valid for one year, and the detailed rationale will be released separately.
Q-Line Biotech Limited has informed the Exchange about Schedule of meeting to be held on 24th July 2026
Intimation · 20 Jul 2026, 11:31 pm
Q-Line Biotech Schedules Virtual Investor Group Meeting for 24th Jul'26 Q-Line Biotech (NSE: QLINE) has scheduled a virtual group meeting with investors and analysts for 3:00 PM on 24th Jul'26. The company confirmed that discussions will be based on publicly available information and no unpublished price-sensitive information (UPSI) will be disclosed. The schedule is subject to change based on exigencies from any of the participating parties.
The Exchange had sought clarification from Q-Line Biotech Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Others (Uncategorized) · 02 Jul 2026, 11:58 pm
Q-Line Biotech Reports Strong FY26 Results with 20.2% Profit Growth Q-Line Biotech reported a standalone net profit of ₹5,694.88 lakhs for FY26, a 20.2% YoY increase. Revenue from operations grew 9.0% YoY to ₹34,115.84 lakhs. For H2'FY26, revenue stood at ₹19,755.66 lakhs with a net profit of ₹3,541.60 lakhs. The company clarified to the exchange that the Certificate of Utilisation of Issue Proceeds was not applicable for the FY26 results as the period pertains to pre-listing, but it will be submitted with results for the half-year ending 30 Sep'26. Basic EPS for FY26 was ₹35.55.
Q-Line Biotech Limited has informed the Exchange about Transcript of Earning call meeting held on 23rd June 2026
Transcript · 01 Jul 2026, 3:20 am
Q-Line Biotech FY26 Results: Margin Expansion and Strong FY27 Growth Guidance Q-Line Biotech reported FY26 revenue of INR341.7 crores, a 9% YoY growth. EBITDA grew 39% YoY to INR98.1 crores, with EBITDA margin expanding 620 bps to 28.7%, driven by higher sales of manufactured reagents and improved product mix. PAT increased to INR55.7 crores from INR19.2 crores. Management guides for 30-35% revenue growth in FY27, focusing on facility utilization, export expansion, and new product launches. The company also aims for INR10 crores from its new CDMO business in its first year.
Q-Line Biotech Limited has informed the Exchange about Schedule of meet proposed to be held on 03rd July 2026 at 03:30 PM
Intimation · 01 Jul 2026, 1:34 am
Q-Line Biotech Schedules Virtual Investor Group Meeting Q-Line Biotech (NSE: QLINE) announced it will participate in a virtual group meeting with investors on 03rd Jul'26 at 03:30 PM. The company confirmed that discussions will be based solely on publicly available information, with no unpublished price sensitive information (UPSI) to be shared. The schedule is subject to potential changes based on exigencies from any of the involved parties. This meeting is disclosed under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
Q-Line Biotech Limited has informed the Exchange about Schedule of meet of Group of Investors
Intimation · 27 Jun 2026, 10:13 pm
Q-Line Biotech (QLINE) Schedules Virtual Investor Meeting Q-Line Biotech Limited (NSE: QLINE) has announced a virtual group meeting with investors scheduled for 03:30 PM on 1st Jul'26. Company officials will participate in the discussion. The company has clarified that the meeting's agenda will be based solely on publicly available information, and no Unpublished Price Sensitive Information (UPSI) will be disclosed. The schedule is subject to potential changes due to exigencies.
The Exchange has sought clarification from Q-Line Biotech Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Others (Uncategorized) · 25 Jun 2026, 4:27 pm